Moderate Cannabis Use Linked to Better Cognition in Older Adults

By Pat Anson

As cannabis use grows among older adults, researchers are beginning to focus on the effects – good and bad — on aging brains.

A recent study found that 18.5% of Americans adults aged 50 to 64, and 5.9% of adults over the age of 65 reported using cannabis products in the past year. About one in four used cannabis for medical purposes.

“More older adults are using cannabis. It's more widely available and is being used for different reasons than in younger folks – such as for sleep and chronic pain,” said Anika Guha, PhD, a clinical psychologist and researcher at the University of Colorado Anschutz Medical Campus. 

“Plus, people are living longer. We have to be asking, ‘What are the long-term effects of cannabis use as we continue to age?’” 

Guha is the lead author of a study, recently published in the Journal of Studies on Alcohol and Drugs, that analyzed the brain scans and cognitive test results of over 26,000 UK adults between the ages of 40 and 77. 

Researchers found larger brain volumes and better cognitive function among middle aged and older adults who used cannabis, especially those who used it moderately. .

“We did see that for many of our outcome measures, moderation seemed to be best. For the brain regions and cognitive tests that demonstrated an effect, the moderate-use group generally had larger brain volumes and better cognitive performance,” Guha explained.  

Moderate use of cannabis was associated with better performance in learning, processing speed, short-term memory, and cognition than non-users. 

Guha was surprised by the extent of the positive findings, but also cautious about interpreting them. Cannabis research is difficult due to the wide range in potency and different forms of ingestion for cannabis products.

Guha and her team are particularly interested in brain regions that have more cannabinoid receptors – called CB1s – which are more likely to be impacted by cannabis use. 

“Some studies will just say there was an impact of cannabis on overall gray (brain) matter. However, we wanted to take a more nuanced approach by looking at effects on specific brain regions, especially those with high CB1 receptor density, as well as on cognitive processes like memory, which is, of course, very relevant to aging,” Guha explained.

“For example, the hippocampus was one of the regions we looked at since it contains many CB1 receptors and plays an important role in memory, especially as we age, and is also implicated in dementia.”

Brain volume has a tendency to shrink as we age, due to atrophy and neurodegeneration. The decrease is often associated with reduced cognitive function and increased dementia risk. 

Cannabis use was associated with reduced volume in only one part of the brain – the posterior cingulate – which helps process memory, learning, and emotion. 

“I think the main takeaway is that the story is nuanced. It’s not a case of cannabis being all good or all bad. I think sometimes people have seen my poster on this project or they see the headline and they say, "Great, I'll just use more cannabis." But it’s more complicated than that,” Guha said. “There’s so much more to explore.”  

Most medical organizations still take a dim view of cannabis. The American College of Physicians (ACP) released a new guideline last year that recommends against the use of medical cannabis.

The ACP said physicians should warn patients that the harms of cannabis outweigh its potential benefits. Medical cannabis may produce small improvements in pain, function and disability, but the ACP warns it could lead to addiction and cognitive issues, as well as cardiovascular, gastrointestinal and pulmonary problems.

How Should the U.S. Regulate Medical Marijuana?

By Chris Meyers

Medical marijuana could soon be reclassified into a medical category that includes prescription drugs like Tylenol with codeine, ketamine and anabolic steroids.

That’s because in December 2025, President Donald Trump signed an executive order to reschedule marijuana to a less restricted category, continuing a process initiated by President Joe Biden in 2022.

Currently, marijuana is in the most restrictive class, Schedule I, the same category as street drugs like LSD, ecstasy and heroin.

For years, many researchers and medical experts have argued that its current classification is a hindrance to much-needed medical research that would answer many of the pressing questions about its potential for medicinal use.

In January 2026, Republican Senators Ted Budd, of North Carolina, and James Lankford, of Oklahoma, introduced an amendment to funding bills trying to block the rescheduling, claiming that it “sends the wrong message” and will lead to “increased risk of heart attack, stroke, psychotic disorders, addiction and hospitalization.”

As a philosopher and drug policy expert, I am more interested in what is the most reasonable marijuana policy. In other words, is rescheduling the right move?

Broadly speaking, there are three choices available for marijuana regulation. The U.S. could keep the drug in the highly restricted Schedule I category, move it to a less restrictive category or remove it from scheduling altogether, which would end the conflict between state and federal marijuana laws.

As of January 2026, cannabis is legal in 40 of 50 states for medical use and 24 states for recreational use. Rescheduling would only apply to medical use.

Let’s examine the arguments for each option under the Controlled Substances Act, which places each prohibited drug into one of five “schedules” based on proven medical use, addictive potential and safety.

Drugs classified as Schedule I – as marijuana has been since 1971, when the Controlled Substances Act was passed – cannot be legally used for medical use or research, though an exception for research can be made with special permission from the Drug Enforcement Administration. Schedule I drugs are believed to have a high potential for abuse, to be extremely addictive and to have “no currently accepted medical use.”

As a Schedule I drug, marijuana has been more tightly controlled than cocaine, methamphetamine, PCP and fentanyl, all of which belong to Schedule II.

Option One: Keep the Status Quo 

Some policy analysts and anti-marijuana activists argue that marijuana should remain a Schedule 1 drug.

A common objection to rescheduling it is the assertion that 1 in 3 marijuana users develop an addiction to the drug, which stems from a large study called a meta-analysis.

A careful reading of that study reveals the flaws in its conclusions. The researchers found that about one-third of heavy users – meaning those who use marijuana weekly or daily – suffered from dependence. But when they looked at marijuana users more generally – meaning people who tried it at least once, the way addiction rates are normally measured – they found that only 13% of users develop a dependency on marijuana, which makes it less habit-forming than most recreational drugs, including alcohol, nicotine and caffeine, none of which are scheduled under the Controlled Substances Act.

Further, if the 1-in-3 figure were accurate, then marijuana would be more addictive than alcohol, crack cocaine and even heroin. This defies both common sense and well-established studies on the comparative risk of addiction.

Critics of rescheduling also deny that there is convincing evidence that marijuana or its compounds have any legitimate medical use. They cite research like a 2025 review paper that assessed 15 years of medical marijuana research and concluded that “evidence is insufficient for the use of cannabis or cannabinoids for most medical indications.”

This claim is problematic, however, given that the Food and Drug Administration has already approved several medicines that are based on the same active compounds found in marijuana. These include the drugs Marinol and Syndros, which are used to treat AIDS-related anorexia and chemotherapy-induced nausea and vomiting. Both of these contain delta-9-tetrahydrocannabinol, or THC, the substance that is responsible for the marijuana high.

If the active ingredients of marijuana have legitimate medical use as established by the FDA, then it stands to reason that so must marijuana.

Option Two: Move Marijuana to Schedule III

Moving marijuana to schedule III would make it legal at the federal level, but only for medical use. Recreational use would remain federally prohibited, even though it is legal in 24 states as of early 2026.

The most obvious benefit to rescheduling, noted above, is that it would make research on marijuana easier. The system of cannabinoid receptors through which marijuana confers its therapeutic and psychoactive effects is crucial for almost every aspect of human functioning. Thus, marijuana compounds could provide effective medicines for a wide variety of ailments.

Contrary to the 2015 review mentioned earlier, studies have shown that cannabis is effective for treating nausea and AIDS symptoms, chronic pain and some symptoms of multiple sclerosis, as well as many other conditions.

Rescheduling could also improve medical marijuana guidance. Under the current system, medical marijuana users are not provided with accurate, evidence-based guidance on how to use marijuana effectively. They must rely on “bud tenders,” dispensary employees with no medical training whose job is to sell product. 

If cannabis were moved to Schedule III, doctors would be trained to advise patients on its proper use. On the other hand, medical schools need not wait for rescheduling. Given that many people are already using medical marijuana, some medical experts have argued that medical schools should provide this training already.

Rescheduling, however, is not without complications. To comply with the law, medical marijuana programs would have to start requiring a doctor’s prescription, just like with all other scheduled substances. And it could be distributed only by licensed pharmacies. That might be a good thing, if marijuana is as dangerous and addictive as critics claim. 

But advocates of medical marijuana might be concerned that this would increase costs to the consumer and restrict access. That concern might be mitigated, however, if health insurance companies are required to cover the costs of medical marijuana once it is rescheduled.

In addition, it is unclear how rescheduling would affect state-level bans on medical marijuana. Generally speaking, states cannot legally restrict access to pharmaceuticals that have been approved by the FDA. However, this principle of federal preemption is currently being challenged by six states claiming they have the authority to restrict access to the abortion medication mifepristone.

Option Three: Unschedule Marijuana

The debate over rescheduling ignores a third option: that marijuana could be removed entirely from the Controlled Substances Act, giving states the authority to allow medical marijuana to be distributed without a prescription.

Some of the objections to rescheduling come from marijuana advocates. Given that marijuana is safer and less addictive than alcohol – which is not scheduled under the Controlled Substances Act – a case could be made for removing it entirely from the list of scheduled substances and allowing states to legalize it for recreational use, as many states have already.

In fact, many drugs as, or more powerful than, marijuana are also not scheduled. For example, most over-the-counter cough medicines contain dextromethorphan, a hallucinogenic dissociative, which in large doses causes effects similar to PCP.

Removing marijuana from the list of controlled substances would also decriminalize the drug. Over 200,000 Americans were arrested for marijuana in 2024, over 90% of them for mere possession.

At the moment, the third option seems very unlikely. Although over 60% of Americans are in favor of full marijuana legalization, it lacks support in Congress.

Medical marijuana rescheduling looks likely to occur in 2026. After all, it has been proposed by both Biden and Trump. Whether it is the right move, only time will tell.

Chris Meyers, PhD, is an Adjunct Professor of Philosophy at George Washington University. 

This article originally appeared in The Conversation and is republished with permission.

The Most Dangerous Drug in Canada Is Not Prescription Opioids

By Pat Anson

The most dangerous drug in Canada doesn’t require a prescription. You can’t smoke, vape, snort, or inject it. It doesn’t come in a pill, patch or edible.

It’s responsible for as many as 18-thousand deaths every year in Canada and can result in a lifetime of addiction. It ruins marriages, families, friendships and careers, and costs society about $20 billion a year in added healthcare expenses and lost productivity.

Yet it is readily available in most stores and can be purchased by anyone over the age of 19. In some provinces, the age limit is 18.

By now you’ve probably guessed that I’m talking about alcohol.

A new report by the Centre for Addiction and Mental Health (CAMH) found that alcohol causes more harm in Canada overall than any other drug — ranking well above tobacco, illicit fentanyl, cocaine, cannabis, methamphetamine and, yes, prescription opioids.

CAMH put together a diverse panel of 20 experts in public health, epidemiology, addiction, criminology, psychology and public policy to assess the short and long-term impact of 16 commonly used psychoactive drugs. In addition to the direct “harm to users” – such as addiction and overdose – they evaluated the indirect “harm to others” – families, communities and society at large.

“This is the first time this approach has been used to assess drug harms in Canada, and it gives us a much more complete picture than we had before,” said Jean-François Crépault, Senior Policy Advisor at CAMH and lead author of the study published in the Journal of Psychopharmacology. 

“When we look at harm to people who use drugs and harm to others together, alcohol clearly stands out. Our findings highlight a major gap between the harms linked to alcohol and the way it is currently regulated in Canada.”

Based on a ranking system of 0 to 100, with zero meaning no harm and 100 being the most harmful, alcohol was given a score of 79, followed by tobacco (45) and non-prescription opioids (33). The latter category includes illicit fentanyl, xylazine, and other opioid-based street drugs.

Cocaine (19), methamphetamine (19), cannabis (15) and crack (10) are next, with “prescription opioids” (8) ranked as the eighth most harmful drug category.

Even that ranking is a bit misleading, as it includes morphine, oxycodone and other pharmaceutical opioids that are diverted and used without a prescription – which probably should be counted as non-prescription opioids.

Prescription opioids were ranked so low in terms of harm, they barely beat out ENDs (7), an acronym for electronic nicotine delivery systems, more commonly known as vapes or e-cigarettes.

Most Harmful Drugs in Canada

JOURNAL OF PSYCHOPHARMACOLOGY

The finding that alcohol causes the most harm aligns with previous studies in the United Kingdom, the European Union, Australia and New Zealand.

In the United States, a recent study that used a slightly different methodology ranked alcohol as the 5th most harmful drug, behind illicit fentanyl, methamphetamine, crack and heroin. Prescription opioids ranked as the 7th most harmful drug in the U.S.

Experts say these studies point to a clear need for government drug policies to better align with the actual harm that a specific drug causes – and not be based on laws, guidelines, class action lawsuits, or whatever drug hysteria is popular at the moment. 

Despite all the harm it causes, no one talks about banning alcohol, yet natural leaf kratom and the kratom extract 7-OH are being demonized as “gas station heroin” and “legal morphine” that should be banned. Never mind that there is little solid evidence they are dangerous when used appropriately. Neither substance made the “harmful” list in Canada, United States, or anywhere else.

“The key message here is that harm is not just about what a drug does to the body,” said Crépault. “How a drug is regulated shapes who uses it, how it is used, and how much harm it causes. Evidence-based policy can significantly reduce harm, and governments have a real opportunity to use regulation to protect public health.”

Medical Cannabis Helps Relieve Fibromyalgia Symptoms

By Pat Anson

Medical cannabis products help relieve pain and anxiety caused by fibromyalgia, and improve sleep and quality of life, according to a new study of patients enrolled in the UK’s Medical Cannabis Registry.

Fibromyalgia is a poorly understood and difficult-to-treat condition that causes widespread body pain, fatigue, insomnia, mood disorders and brain fog. 

The UK study of nearly 500 fibromyalgia patients found the greatest improvement in symptoms when participants took higher doses of cannabidiol (CBD) daily over an 18-month period. Higher CBD doses were associated with better outcomes compared to lower doses, and current cannabis users saw better results than those who had never tried it before. 

Participants were initially prescribed a cannabis oil, but as the study progressed, most began to use a mixture of oils taken orally and dried flowers inhaled through a vaporizer. The median CBD dosage increased during the study, from 20mg a day at the start to 25mg at the end, which is considered a moderate to strong dose. 

Tetrahydrocannabinol (THC) content also increased, from a median of 2mg a day at the start of the study to 112.5mg at the end – a high dose likely to cause a strong buzz. But high THC doses were not associated with an improvement in symptoms.

The UK study contradicts a recent U.S. study that found THC more effective in relieving pain than CBD. However, that study primarily involved synthetic FDA approved cannabis-based medicines, such as dronabinol and nabilone, which are approved to reduce nausea and increase appetite – not for pain relief. The UK study involved products that cannabis consumers are much more likely to use.

In the UK, fibromyalgia patients are only eligible to be prescribed “unlicensed” medical cannabis if they have failed to gain improvement in symptoms from licensed pharmaceutical medicines. 

Nearly half of the participants reported mild to moderate side effects, with fatigue and dry mouth being the most common. Researchers believe the high rate of adverse events (AEs) stem from fibromyalgia’s central sensitization effects, which increase the nervous system’s sensitivity to new stimuli. 

“This study found treatment with CBMPs (cannabis-based medicinal products) in fibromyalgia was associated with short to medium-term improvements in pain, anxiety, sleep, and general quality of life. There was a high incidence of AEs, perhaps due to its central sensitisation mechanism, associated with an increased susceptibility to AEs,” the authors reported in the journal Clinical Rheumatology.

Researchers say the improvement in fibromyalgia symptoms had a waning effect as the study progressed, with peak improvement at 1 month and the lowest after 18 months.

Previous studies in Israel and Brazil have also found that cannabis products improve fibromyalgia symptoms.

The amount of THC – the psychoactive ingredient in cannabis – consumed in the UK study was unusually high. After 18 months, the median dose was 112mg of THC a day, with some participants taking nearly 217mg daily.

Another team of UK researchers recently recommended that adults not consume more than 40mg of THC a week – or about 5.7mg a day. Higher THC doses are associated with increased rates of cannabis use disorder.

Review Finds THC More Effective Than CBD for Chronic Pain

By Pat Anson

An updated systematic review found that cannabis products with relatively high levels of THC (tetrahydrocannabinol) may provide small improvements in chronic pain; while those containing high levels of CBD (cannabidiol) and little or no THC had minimal effect on pain.

Researchers at the Pacific Northwest Evidence-based Practice Center at Oregon Health & Science University reviewed 25 short-term cannabis studies involving over 2,300 patients with chronic pain. Their findings are published in the Annals of Internal Medicine. 

CBD-based gummies, tablets, oils and other products have long been marketed for various health issues, but researchers say they demonstrated almost no improvement in managing pain. 

“This may be surprising to people,” said lead author Roger Chou, MD, in a press release. “Conventional wisdom was that CBD was promising because it doesn’t have euphoric effects like THC and it was thought to have medicinal properties. But, at least in our analysis, it didn’t have an effect on pain.” 

Chou, who was lead author of the controversial 2016 CDC opioid guideline and its 2022 update, said the small improvement in pain was on the order of a half point to a point on the zero-to-10 pain scale. While providing modest pain relief, THC-based products also had a higher risk of side effects, such as dizziness, sedation and nausea.   

There are several caveats to the review which make it unhelpful, at best, in determining whether THC or CBD are effective pain relievers. 

One, many of the clinical trials were deemed to be biased or of low quality. They mostly involved patients with chronic neuropathic pain, which means they don’t necessarily apply to patients with other types of pain.

Second, most of the studies involved pharmaceutical-grade cannabis-based medicines, such as dronabinol and nabilone, which are approved for nausea, vomiting and as an appetite stimulant. None of them are approved for pain relief.  

Third, those pharmaceutical medicines are based on synthetic THC, not plant-derived THC or CBD. So basically, the researchers studied products that most cannabis consumers don’t use, which makes the overall findings misleading.

“This raises critical questions about generalizability: Can findings from standardized formulations inform real-world use of diverse, cannabis-derived, state-regulated products?” asks Ziva Cooper, PhD, from the UCLA Center for Cannabis and Cannabinoids, in an editorial also published in the Annals of Internal Medicine.   

Copper says the review demonstrates the need for better evidence and less reliance on clinical trials. The inclusion of observational studies and patient reviews of products obtained in dispensaries would better capture real-time evidence of current cannabis use and outcomes. 

“There are opportunities for novel approaches to understand cannabis-related health effects. Rigorous randomized controlled trials (RCTs) are the gold standard for determining the safety and efficacy of cannabis and cannabinoids for therapeutic end points,” Cooper wrote. 

“Yet, these studies are resource-intensive, challenging due to federal regulations, and slow to adapt to a rapidly evolving marketplace and patient behavior. Expanding the scope of study designs to consider complementary strategies is urgently needed.”

Chou says the wide variety of cannabis products on the market makes drawing conclusions about their effectiveness difficult.

“It’s complicated because cannabis products are complicated,” he said. “It’s not like taking a standardized dose of ibuprofen, for example. Cannabis is derived from a plant and has multiple chemicals in addition to THC and CBD that may have additional properties depending on where it’s grown, how it’s cultivated and ultimately prepared for sale.”  

Better cannabis research is one of the reasons the Trump Administration is moving to complete the process of reclassifying cannabis from a Schedule I controlled substance to a Schedule III drug with accepted medical uses.

Because cannabis has long been illegal under federal law, it has stifled research into its health benefits, leaving patients and doctors in the dark on its potential uses. This review does nothing to shine a light on the issue.  

Cannabinoids and Pain Care: A Federal Shift That Needs Guardrails

By Dr. Lynn Webster

On December 18, President Trump signed an executive order directing the Department of Justice to expedite completion of the process moving marijuana from an illegal Schedule I controlled substance to Schedule III, a less restrictive category that allows for medical use.

The order also directs federal health agencies to expand research, explicitly including real-world evidence, to better inform patients and clinicians about medical marijuana and hemp-derived cannabidiol (CBD).

For clinicians who treat chronic pain, the significance is simple. Federal policy is starting to align with clinical reality. Cannabinoids are already widely used for pain and related symptoms, yet clinical guidance and product standards have lagged.

What the Order Gets Right

It squarely names the research gap. The order cites FDA’s review finding scientific support for marijuana’s medical use in specific settings (including pain), and it connects the current rescheduling effort to the Department of Health and Human Service’s 2023 recommendation that marijuana be placed in Schedule III.

Whatever one thinks about cannabis politics, Schedule I status did not prevent use — it contributed to widespread use with limited standardization and weak clinical guidance.

It also highlights a practical safety problem that clinicians recognize immediately: non-disclosure by patients. The order cites survey data that only about 56% of older adults using marijuana have discussed it with a healthcare provider.

This is an avoidable risk in a population where polypharmacy is common, and adverse events can be consequential. Normalizing nonjudgmental conversations about cannabinoid use is low-tech harm reduction.

Another constructive element is that the order explicitly calls for a regulatory framework for hemp-derived cannabinoid products, including guidance on an upper limit of THC per serving and considerations such as per-container limits and CBD:THC ratio requirements.

Where the Risks Remain

Rescheduling is not the finish line. Moving marijuana to Schedule III may improve research, but it does not automatically create FDA-approved medications, standardized dosing, or clinically reliable formulations for the products most patients actually use. If the public interprets Schedule III as “safe and proven,” we may inadvertently widen the gap between perception and evidence.

CBD is the other major vulnerability. The order acknowledges that some commercially available CBD products are inaccurately labeled (for example, isolate vs. broad-spectrum vs. full-spectrum), leaving patients and clinicians without adequate safeguards. Independent testing supports this concern. A JAMA analysis of CBD products sold online found substantial labeling inaccuracies and detectable THC in a meaningful share of samples.

In pain care, that matters. Unintended THC exposure can impair cognition, contribute to sedation and increase fall risk, especially in older adults. It can also trigger unexpected positive drug tests with real-world consequences.

Safety signals also deserve more humility than the marketing suggests. FDA warns that CBD can cause liver injury and affect how other drugs work, potentially leading to serious side effects.

A randomized clinical trial in healthy adults reported liver enzyme elevations in a subset receiving CBD 5 mg/kg/day for 28 days, with some meeting protocol criteria for potential drug-induced liver injury.

The takeaway from this is not “CBD is dangerous.” It is that population-level use without dose clarity, interaction guidance, or monitoring invites harm, especially in older adults, medically complex patients, and in people taking anticoagulants, anti-epileptics, sedatives or other CNS-active medications.

Finally, the order hints at regulatory whiplash around “full-spectrum” products, noting that some could be treated as controlled substances — again, depending on statutory THC thresholds.

Shifting definitions and enforcement create confusion for patients, clinicians and legitimate manufacturers, and can favor market consolidation that raises prices and narrows choice.

A Clinician’s Checklist for Doing This Right

If this federal pivot is going to improve pain care, access must be paired with guardrails including:

1. Product integrity first. Batch testing, contaminant screening, and accurate labeling (including verified CBD and THC per serving, and spectrum classification) for any federally supported access or research model.

2. Pharmacovigilance at scale. If real-world evidence is the strategy, real-world safety reporting must be built in and transparent.

3. Routine medication reconciliation. Clinicians should ask about cannabinoid use the way we ask about supplements — calmly, consistently, and without stigma.

4. Honest messaging. Clear statements about what the evidence supports, what remains uncertain, and what warrants extra caution.

Bottom Line

The executive order is an important acknowledgement that Americans are using cannabinoids for pain while federal research, standards, and safeguards have lagged. If rescheduling accelerates rigorous research and CBD access is paired with product standards and safety monitoring, clinicians and patients could benefit.

But if access expands faster than quality control and pharmacovigilance, we risk repeating a familiar U.S. cycle: adoption first, guardrails later. Cannabinoids give us a chance to do it differently: evidence first, standards always, and patient safety at the center.

Lynn R. Webster, MD, is a physician specializing in pain and addiction medicine, a former president of the American Academy of Pain Medicine, Senior Fellow at the Center for U.S. Policy, and author of “The Painful Truth” and the forthcoming book “Deconstructing Toxic Narratives: Data, Disparities, and a New Path Forward in the Opioid Crisis.”

Lynn has written extensively on drug policy, the opioid crisis, and criminalization of medicine. Webster reports no relevant financial relationships related to cannabis or CBD products. 

Executive Order Rescheduling Cannabis Won’t Help Pain Patients Anytime Soon

By Crystal Lindell

This week, President Donald Trump signed an executive order that aims to reclassify cannabis as a less dangerous drug, but the move stopped short of making it federally legal.

The order directs Attorney General Pam Bondi to complete the process of reclassifying cannabis from an illegal Schedule I controlled substance to a Schedule III drug with lower abuse potential and accepted medical uses, in the same category as codeine and ketamine. President Biden started that process three years ago.

It’s important to note that moving cannabis to Schedule III will not legalize it for recreational use nationwide. And it will be up to the FDA to determine what an “accepted medical use” is for cannabis-based medicines.

The White House specifically mentioned chronic pain as one of the medical conditions that cannabis could help treat, noting that six in 10 people who use medical marijuana in the states where it is legal do so to manage pain.

"We have people begging for me to do this, people that are in great pain for decades," President Trump said. "I'm not gonna be taking it. But a lot of people do want it. A lot of people need it.

"The facts compel the federal government to recognize that marijuana can be legitimate in terms of medical applications when carefully administered. In some cases, this may include the use as a substitute for addictive and potentially lethal opioid painkillers. They cause tremendous problems. [Cannabis] can do it in a much lesser way. It can make people feel much better that are living through tremendous pain and problems." 

In addition to rescheduling, the Trump Administration is trying to expedite medical research so that CBD and hemp-based cannabis products can be legally sold nationwide. Those products are not FDA-approved, putting them in a legal limbo under federal law.

“In short, the current legal landscape leaves American patients and doctors without adequate guidance or product safeguards for CBD,” Trump said in a statement. “It is critical to close the gap between current medical marijuana and CBD use and medical knowledge of risks and benefits, including for specific populations and conditions.”

My hope is that pharmaceutical companies will finally be able to tap into cannabis’ full potential as a medical treatment and develop new drugs. Once they find the best ways to produce it, dose it, conduct clinical trials, and get FDA approval, then cannabis-based drugs could potentially help millions of pain patients. . 

Of course, that process could take years or perhaps even decades, so the odds are that many pain patients will remain reliant on CBD, hemp-based products, and marijuana dispensaries. That’s if cannabis is even legal in their state. 

Plus, whenever we do get pharmaceutical cannabis products, the next barrier will likely be price. Medical and recreational cannabis sold in dispensaries is more expensive than street supply, and I’m sure pharmaceutical companies will mark it up even more. But at least then it could be covered by insurance. 

Looking back, it seems obvious that cannabis should have never been classified as a Schedule I substance to begin with, as there are clearly multiple medical uses for it.

I am old enough to remember a time before any states had even legalized it, when the idea of it even being re-classified federally was a pipe dream.

I remember guys I knew in college in the early 2000s puffing away and going on and on about how one day marijuana would be legal. I would look at them with extreme skepticism. But as it turns out, they were basically right – at least in states like California and Colorado where recreational cannabis is legal. 

The Trump administration still has not made cannabis fully legal, but we are on track to see it happen.

Any time there’s a major change in the U.S. drug policy like this, it is worth noting how arbitrary much of it can be. Very little of it seems based on actual medical reasoning. It’s more about law enforcement and turning substances into villains.  

After all, if the stroke of a pen can move a drug from one controlled substances category to another — suddenly making them legal — perhaps the categories themselves are poorly designed. That logic follows when you see how the federal government handles things like opioids and kratom. You should not accept their reasoning at face value. 

We should all remain skeptical whenever the government tries to say any drug is inherently bad – especially when it tries to enforce such a classification with jail time and fines. Because clearly, their definition of “bad” and a medically-backed definition of “bad” are not the same thing.

Mixed Findings on Effectiveness of Medical Cannabis

By Pat Anson

Some new studies are muddying the water even more on whether medical cannabis is an effective treatment for pain, anxiety, insomnia and other health conditions. 

The first study, a JAMA review of over 120 clinical trials, medical guidelines and meta-analyses (studies of studies), found that there is not enough scientific evidence to support most of the conditions that cannabis is commonly used to treat.

Over one in four (27%) adults in the United State and Canada have used cannabis for medical purposes. And over 10% of people in the U.S. have used products containing cannabidiol (CBD) for therapeutic purposes.

But researchers say that widespread use is driven more by perceptions, anecdotes and promotion than it is by scientific evidence.

"While many people turn to cannabis seeking relief, our review highlights significant gaps between public perception and scientific evidence regarding its effectiveness for most medical conditions," says lead author Michael Hsu, MD, a psychiatrist and health researcher at UCLA Health. “Patients deserve honest conversations about what the science does and doesn't tell us about medical cannabis.”

Hsu and his colleagues found that FDA-approved cannabis-based medications, such as dronabinol and nabilone, are effective for HIV/AIDS-related appetite loss, chemotherapy-induced nausea, and pediatric seizure disorders such as Dravet syndrome and Lennox-Gastaut syndrome.

But for most other conditions, the evidence remains either inconclusive or lacking. Over half of medical cannabis users take it for chronic pain, but current medical guidelines recommend against cannabis as a first-line treatment for either chronic or short-term acute pain.

The researchers also highlighted the potential health risks of cannabis. High-potency cannabis containing over 10% THC has been linked to higher rates of psychotic symptoms and anxiety disorder. Daily use of cannabis, particularly of inhaled or high-potency products, is also associated with higher rates of coronary heart disease, heart attack and stroke compared to non-daily use.

About 29% of people who use medical cannabis also met the criteria for cannabis use disorder.

The review emphasizes that doctors should screen patients for cardiovascular disease and psychotic disorders, and evaluate them for potential drug interactions, before recommending THC-containing products for medical purposes.

Medical Cannabis Reduces Opioid Use

But another study, published in JAMA Internal Medicine, suggests that medical cannabis is an effective treatment for chronic pain because it reduces the use of prescription opioids.

Researchers at Albert Einstein College of Medicine and Montefiore Health System evaluated 204 adults in New York State’s Medical Cannabis Program who were prescribed opioids for chronic pain between 2018 and 2023.  

At the start of the study, most participants reported high levels of pain (an average of 6.6 on the zero to 10 pain scale) and were taking an average daily dose of 73.3 morphine milligram equivalents (MME). By the end of the 18-month study, the average daily dose fell to 57 MME, a 22% reduction.

“Our findings indicate that medical cannabis, when dispensed through a pharmacist-supervised system, can relieve chronic pain while also meaningfully reducing patients’ reliance on prescription opioids,” said lead author Deepika Slawek, MD, an associate professor of medicine at Einstein, and an internal medicine and addiction medicine specialist at Montefiore. 

The reduced use of opioids suggests that chronic pain sufferers can be slowly weaned off opioids with medical cannabis. For example, participants who received a 30-day supply of medical cannabis reduced their opioid use by an average of 3.5 MME compared to non-users.

“Those changes may seem small, but gradual reductions in opioid use are safer and more sustainable for people managing chronic pain than stopping suddenly,” said Slawek.

Since the study occurred during a time period when opioid prescribing overall fell by nearly 50% in the United States, we asked Dr. Slawek if that could have influenced the findings. She said researchers adjusted their modeling data to account for that as best they could.

“The only way that we will be able to get definitive answers on whether medical cannabis reduces opioid use is to conduct randomized trials, which are very difficult to do in the U.S. specific to cannabis,” Slawek told PNN in an email. “We believe that by using causal inference modeling in this study, we were able to add the highest quality evidence possible that cannabis may reduce opioid use in patients with chronic pain.” 

The scientific data for medical cannabis is improving. According to an analysis by the National Organization for the Reform of Marijuana Laws (NORML), the number of cannabis research studies grew for the fifth consecutive year, with over 4,000 scientific papers involving cannabis published so far in 2025.

“Despite the perception that marijuana has yet to be subject to adequate scientific scrutiny, scientists’ interest in studying cannabis has increased exponentially in the past decade, as has our understanding of the plant, its active constituents, their mechanisms of action, and their effects on both the user and upon society,” said NORML Deputy Director Paul Armentano. 

“It is time for politicians and others to stop assessing cannabis through the lens of ‘what we don’t know’ and instead start engaging in evidence-based discussions about marijuana and marijuana reform policies that are indicative of all that we do know.”

According to NORML’s analysis, over 37,000 scientific papers about cannabis have been published since 2015. That means over 70% percent of all peer-reviewed scientific papers about cannabis have been published in the past ten years alone.    

The studies are growing and so is the anecdotal evidence. A recent survey of 1,669 medical cannabis users in the UK found that nearly 89% of those with chronic pain reported somewhat improved or significantly improved quality of life.

Middle-Aged Adults Increasingly Identify as Cannabis Consumers

By Pat Anson

Cannabis use continues to grow among older Americans, according to a new study that found nearly one in five middle-aged adults consumed cannabis within the past year.  

The study by researchers at Columbia University is based on data from the 2022 Health and Retirement Study — a nationwide survey of older adults.

Researchers reported that 18.5% of adults aged 50 to 64, and 5.9% of adults over the age of 65 acknowledged using cannabis products in the prior year. The findings are consistent with previous studies that found rising percentages of middle-aged and older adults consuming marijuana products. Smoking was the primary way used to consume cannabis in both groups.

About 25% of middle-aged and 20% of older cannabis users said they used it for medical purposes. Over 75% of respondents in both age groups supported the medical use of cannabis, but researchers sounded a note of caution about its growing acceptance.

“Cannabis use among both middle-aged and older U.S. adults is higher than previously reported in state and national-level studies, with many engaging in cannabis behaviors associated with increased harm. Greater public health and clinical efforts are needed for tailored prevention and intervention strategies,” Columbia researchers reported in the American Journal of Preventive Medicine.

While cannabis use is growing for therapeutic purposes, most medical organizations still frown on it. The American College of Physicians (ACP) recently released a new guideline that recommends against the use of medical cannabis for most patients with chronic noncancer pain.

The ACP said physicians should warn patients that the harms of cannabis use outweigh their potential benefits. Medical cannabis may produce small improvements in pain, function and disability, but the ACP warns it could lead to addiction and cognitive issues, as well as cardiovascular, gastrointestinal and pulmonary problems.

A large study in the UK recently found that cannabis use may actually benefit older adults by slowing the aging of brains and improving cognitive function. Normal aging typically involves a gradual decline in cognitive abilities, but when researchers compared the cognitive performance of cannabis users and non-users, they found that cannabis users had better cognitive function and had brain characteristics “typically associated with younger brains.“  

“It is not surprising that a growing percentage of adults consider cannabis to be a viable option in their later years,” said Paul Armentano , Deputy Director of NORML, a marijuana advocacy group.

“Many middle-aged and older adults struggle with pain, anxiety, restless sleep, and other conditions that cannabis products can mitigate. Many older adults are also well aware of the litany of adverse side effects associated with available prescription drugs, like opioids or sleep aids, and they see medical cannabis as a practical and potentially safer alternative.”

A recent analysis found that medical cannabis is most effective for managing neuropathic pain, but doesn’t work as well for migraine, headache and acute pain. The report by Green Health Docs, a company that connects patients with licensed medical marijuana doctors, is based in part on a survey of 1,450 patients who use medical cannabis.

The vast majority (86%) of those surveyed reported moderate-to-significant pain improvement. Many patients were able to reduce or stop using opioids and other prescribed analgesics once they started using medical cannabis.

Cannabis Reduces Use of Opioids by Cancer Patients

By Pat Anson

The opening of cannabis dispensaries is associated with a significant decline in opioid prescriptions, according to a large new study that suggests cannabis is effective for cancer pain and reduces the need for opioids.

Researchers analyzed the health records of over 3 million commercially insured patients enrolled in Optum, the health services arm of UnitedHealth Group, and focused on those who had a cancer diagnosis.

Cancer patients who lived in states with medical or recreational cannabis dispensaries had significantly lower rates of opioid prescriptions, a lower daily supply of opioids, and fewer prescriptions per patient.

Although the study did not look at a cause-and-effect relationship between cannabis and relief from cancer pain, researchers say their findings suggest that cannabis can be an effective substitute for opioids.

Cancer pain is one of the most commonly approved conditions for medical cannabis, but there has been limited research on whether cannabis is an effective analgesic for cancer pain.

“Results of this study suggest that cannabis may serve as a substitute for opioids in managing cancer-related pain, underscoring the potential of cannabis policies to impact opioid use,” researchers reported in JAMA Health Forum.

“While opioids remain the recommended treatment for cancer pain, these patients may benefit from cannabis availability for adjuvant therapy. Further, cannabis use may reduce opioid use more among patients with cancer whose pain is not well managed with opioids or who experience negative effects of opioid use.”

Researchers believe cancer patients with lower pain levels are more likely to substitute cannabis for opioids once cannabis becomes an option.

Although opioid use by cancer patients is lower in states where medical and recreational cannabis are legal, the most significant reductions were in states with medical cannabis dispensaries. The rate of patients with opioid prescriptions was over 24% lower where there was access to a medical dispensary, while the daily supply of opioids was nearly 10% lower and the number of prescriptions per patient was over 5% lower.

Smaller reductions in opioid prescribing were associated with recreational cannabis dispensaries.   

Although cancer patients are exempt from most medical guidelines that discourage the use of opioids, many were still cutoff from opioids or had their doses reduced by doctors. A recent study found a 24% decline in opioid prescribing to Medicare patients with cancer after the CDC’s 2016 opioid guideline was released.

Last year, the FDA shutdown a special program that supplied potent fentanyl lozenges and tablets to patients suffering from severe cancer pain. The FDA decision came after it was notified by Teva Pharmaceutical that it would no longer make fentanyl lozenges or tablets.

It could become even harder for some cancer patients to obtain opioids. VA researchers recently proposed that cancer patients no longer be exempt from VA and Department of Defense guidelines that discourage the prescribing of opioids for chronic pain. The researchers said cancer patients were living longer and were at risk of “persistent opioid use.”    

Cannabis Extract Provides ‘Superior Pain Relief’ Compared to Opioids

By Pat Anson

A German pharmaceutical company has released the results of two late-stage clinical trials, showing that a cannabis extract called VER-01 significantly reduces chronic lower back pain. The full spectrum extract, derived from cannabis sativa, provided better pain relief to patients in a head-to-head comparison with low doses of opioids.

Vertanical hopes to get regulatory approval of VER-01 in Europe and with UK regulators in 2026. If granted, VER-01 would be the first cannabis-based medicine approved for use in treating chronic pain. Another study of VER-01 is planned in the U.S. next year, which would be a step towards getting FDA approval.

Findings from the two Phase 3 studies were published separately in the journals Nature Medicine and Pain & Therapy.

“These findings provide powerful evidence that VER-01 could in the future transform how we care for patients with chronic lower back pain,” co-author Charles Argoff, MD, Professor of Neurology at Albany Medical College and past president of the American Academy of Pain Medicine, said in a press release.

“The results of the Phase 3 studies bring hope to millions living with chronic pain that VER-01, once approved, may provide effective pain relief without the risks and harms associated with existing therapies.”

Chronic lower back pain (CLBP) affects more than half a billion people worldwide and is the leading cause of disability. Current treatment options for CLBP are typically limited to physical therapy and non-steroidal anti-inflammatory drugs (NSAIDs), which often don’t work.

In the Phase 3 study, 820 patients with CLBP were given either a placebo or VER-01 over 12 weeks. Those who received the extract had an average pain reduction of 1.9 points on a zero-to-ten pain scale. After six months, pain intensity decreased by 2.9 points, which was sustained over 12 months. Participants also reported improvements in neuropathic pain, sleep quality and physical function.

The other Phase 3 study involved 384 patients with CLBP, who received either VER-01 or opioids for six months. Opioid doses started with a mean daily average of nearly 27 morphine milligram equivalents (MME) and were titrated up to an average of nearly 32 MME, a dosage range that would be considered low or moderate. Opioid options included tramadol, oxycodone, hydromorphone, morphine, and transdermal fentanyl or buprenorphine.

VER-01 was more effective in relieving pain than opioids, especially for patients with severe pain. The average pain reduction with VER-01 was 2.5 points on the pain scale, compared to 2.16 points with opioids. Patients taking VER-01 also had better sleep quality and were less likely to be constipated.

VER-01 was generally well tolerated in both studies, with no evidence of dependence or withdrawal. Side effects such as dizziness and nausea were mild and short-term. Although it contains THC, the main psychoactive substance in cannabis, patients did not become “high” or intoxicated. Each dose of VER-01 contained 2.5 mg of THC, as well as cannabinoids, terpenes and other bioactive compounds that were administered twice daily.

“This study provides robust evidence that VER-01 offers better tolerability, as well as superior pain relief and sleep quality compared to opioids in patients with CLBP. These findings highlight its potential as a promising new pharmacological option within a multimodal treatment approach that could fundamentally shift the paradigm in the treatment of chronic pain,” researchers concluded.

It approved, VER-01 would be sold under the brand name Exilby and be taken orally in drops. Vertanical is also studying VER-01 as a pain treatment for patients with osteoarthritis and peripheral neuropathy.

Research into the pain-relieving properties of cannabis has been slow in the U.S., in large part because of marijuana’s status as an illegal Schedule 1 controlled substance. Although the DEA allows more cannabis to be used for research purposes, the agency has dragged its feet about reclassifying marijuana as a Schedule 3 substance that could be used for medical purposes. Until marijuana is rescheduled, VER-01 is unlikely to get FDA approval. 

Medical Cannabis Helps Insomnia Patients Sleep and Reduces Pain

By Pat Anson

Insomnia patients taking medical cannabis reported better sleep quality, as well as less anxiety, depression and pain, according to a new study published in PLOS Mental Health.

The study is notable because it showed sustained improvement in symptoms over 18 months of treatment with medical cannabis. Most previous studies are much shorter.

Researchers at Imperial College London followed 125 patients diagnosed with an insomnia disorder who were prescribed medical cannabis and enrolled in the UK Medical Cannabis Registry. Participants either ingested cannabis oil, smoked dried flower, or a combination of the two. Improvements in sleep and other symptoms were observed after one month of treatment and continued over the 18-month course of the study.

However, the magnitude of improvement declined over time, suggesting that some patients developed tolerance to cannabis. Less than 10% of patients reported mild side effects, such as dry mouth, insomnia and fatigue.

“Over an 18-month period, our study showed that treatment for insomnia with cannabis-based medicinal products was associated with sustained improvements in subjective sleep quality and anxiety symptoms. These findings support the potential role of medical cannabis as a medical option where conventional treatments have proven ineffective,” said co-author Simon Erridge, a PhD candidate at Imperial College and Research Director at Curaleaf Clinic, a cannabis dispensary.

“Conducting this long-term study provided valuable real-world evidence on patient outcomes that go beyond what we typically see in short-term trials. It was particularly interesting to observe signs of potential tolerance over time, which highlights the importance of continued monitoring and individualised treatment plans.”

The researchers say larger clinical trials are needed to confirm their finding of long-term efficacy. Most of the researchers are either employees or medical practitioners at Curaleaf Clinic.

A previous study conducted in Israel also found that cannabis helps with sleep, but regular use lead to drug tolerance and even more sleep problems. Over time, the benefits of cannabis were reversed, with frequent users finding it harder to fall asleep and waking up more often during the night.  

Cannabis Use by Older Adults Linked to ‘Younger Brains’ and Improved Cognition

By Crystal Lindell

A new study suggests that cannabis use by older adults slows the aging of their brains and may even improve cognitive function.  

An international research team analyzed extensive health data on over 25,000 adults in the UK, looking at the relationship between cannabis use, aging, and cognitive function. They found that cannabis users had brain characteristics “typically associated with younger brains “ and “enhanced cognitive abilities.” 

“Cannabis users exhibited superior performance across multiple cognitive domains, and interestingly, the effects of cannabis and cognition are presented concurrently across a range of brain systems,” the authors said.

“These findings suggest that cannabis use may be associated with a deceleration of neural aging processes and the preservation of cognitive function in older adults.”

It’s important to note that the study is a preprint, published in Research Square, which means the findings have not yet been peer-reviewed by a medical journal and may undergo changes. 

While it’s common knowledge that cannabis can alter mood, cognition and perception, researchers wanted to look at other potential impacts, particularly in older adults. Most previous studies investigating the effects of cannabis on brain function focused on adolescents and young adults.

Due to legalization, cannabis is increasingly being used by older adults and there’s a growing recognition that cannabis can be used therapeutically to treat pain, insomnia, depression and other conditions associated with old age.  

Normal aging typically involves a gradual decline in cognitive abilities, but when researchers compared the cognitive performance of cannabis users and non-users, they found that  cannabis use had positive effects on most cognitive functions compared to normal aging.

Cannabis users performed better in various cognitive tasks, including problem solving, planning skills, numeric memory, intelligence, and vocabulary. The effects — where cannabis users outperform non-users — were evident across different age groups, starting in middle age (45–55 years) and continuing into old age (66 + years)

Researchers think cannabis enhanaces cognitive performance by improving how different parts of the brain communicate with each other, a process known as functional network connectivity (FNC).

“Our findings reveal that cannabis usage and healthy aging are associated with overlapping brain network configurations, particularly within the FNC between subcortical and sensorimotor regions, as well as between subcortical and cerebellar areas, albeit with significantly reversed effects,” they said.

The enhanced performance of these brain regions may be due to higher concentrations of cannabinoid receptors in brain tissue, which makes them more responsive to cannabinoids such as tetrahydrocannabinol (THC) and cannabidiol (CBD).

Researchers say their findings could lead to further research into whether cannabinoids and endocannabinoids could be used to treat multiple sclerosis, Parkinson's disease, Alzheimer's disease, and other neurodegeneration diseases.

Large Study Finds Medical Cannabis ‘Effective Treatment’ for Chronic Pain

By Pat Anson

Medical cannabis is an “effective treatment option” for chronic pain and significantly improves quality of life in long-term users, according to a large new study.

Researchers at George Mason University and the medical cannabis telehealth company Leafwell analyzed healthcare trends for over 5,200 chronic pain patients. Those who had used medical marijuana for at least one year reported fewer unhealthy days and significantly better quality of life. They also had slightly fewer emergency department and urgent care visits than non-users.

“The findings of this study suggest, in line with existing research, that medical cannabis is likely an effective treatment option for patients with chronic pain. Moreover, we found that, in addition to an increase in QoL (quality of life), medical cannabis exposure is associated with lower risk of urgent care and ED visits, when comparing patients who used medical cannabis for at least one year to cannabis-naïve patients,” researchers reported in the journal Pharmacy.

“This underscores the potential for not only QoL gains associated with medical cannabis use, but also positive downstream effects on the healthcare system resulting from treatment.”

The study did not distinguish between the types of medical cannabis consumed or what kind of chronic pain conditions that participants had. Most of the researchers work for Leafwell, which helps patients get medical marijuana cards in states where it is legal. The company does not manufacture or sell cannabis products.

Pain Relief #1 Reason for Use 

Pain relief is the most likely reason for people to use cannabis for medical reasons, followed by those seeking help with sleep, anxiety and stress, according to a new survey of over 4,000 cannabis users in California.

There were distinct differences between participants who used cannabis solely for medical reasons and those who used it for both medical and recreational purposes.

Medical users were more likely to be female, and to live in households with children. Their average age at first use was 34, compared to 23 among combined users, who were more likely to be male.

Medical users spent less money on cannabis, about $127 per month, compared to combined users ($186), and used it far less frequently (1-3 times a week vs. multiple times a day).

Medical users also had less desire to “feel the high” from cannabis (42% vs. 75%).

Medical/recreational users were more likely to smoke dried flower (65%), while medical users preferred edibles (48%), topical ointments (28%) and oils (18%).

“Cannabis use is growing with expanding legalization, necessitating more research to understand the ramifications of increased access, and better understand the factors influencing the choices and options available to users. Special attention should be given to medicinal users, who may represent a vulnerable group seeking symptom relief,” researchers at UC San Diego reported in the Journal of Cannabis Research.

While medical cannabis is gaining in acceptance, many healthcare providers still take a dim view of it. The American College of Physicians (ACP) recently released a cautious new guideline that recommends against the use of medical cannabis for most patients with chronic noncancer pain. Medical cannabis may produce small improvements in pain, function and disability, according to the ACP, but potential harms include addiction and cognitive issues, as well as cardiovascular, gastrointestinal and pulmonary problems.

THC-Dominant Cannabis Effective in Treating Anxiety and Depression

By Pat Anson

As many pain sufferers already know, anxiety and depression are common when you live with poorly treated chronic pain.

A recent study found that 40% of adults with chronic pain have clinical symptoms of depression or anxiety. Pain sufferers with fibromyalgia were particularly vulnerable to emotional stress, along with those who are younger and female.   

New research suggests that medical cannabis could be an alternative to antidepressants and anti-anxiety drugs like Xanax. The small observational study, recently published in the Journal of Affective Disorders, found that adults with and without pain experienced significant and sustained relief from anxiety and depression after they started using medicinal cannabis.

Researchers at Johns Hopkins University School of Medicine and La Trobe University followed 33 volunteers in Maryland over a six-month period. Participants completed assessments of their anxiety and depression at the start of treatment, and at one, three, and six months after beginning cannabis use.

Most participants selected cannabis products containing tetrahydrocannabinol (THC), the psychoactive ingredient in cannabis, and experienced clinically significant reductions in anxiety and depression within three months. Acute or immediate relief was dose-dependent, with participants who ingested 10–15 mg of oral THC or at least 3 puffs of vaporized cannabis reporting the most relief from anxiety and depression.

There are some caveats about using higher doses. Participants reported feeling “high” using THC-dominant cannabis, and some were so impaired it affected their driving abilities. But overall, the results were positive.

“Initiation of THC-dominant medicinal cannabis was associated with acute reductions in anxiety and depression, and sustained reductions in overall symptom severity over a 6-month period. Controlled clinical trials are needed to further investigate the efficacy and safety of medicinal cannabis for acute anxiety and depression symptom management,” researchers reported.

Previous studies have also suggested that medical cannabis is most effective when it also contains THC.

A recent study of 64 patients in Germany with inadequately treated chronic pain found that a cannabis extract with equal parts THC and CBD (cannabidiol) substantially reduced their self-reported pain intensity.

“Our findings indicate that treatment with medicinal cannabis improves both physical and mental health in patients with chronic pain,” researchers reported in the journal Advances in Therapy. “The results suggest that medicinal cannabis might be a safe alternative for patients who are inadequately treated with conventional therapies.”

In a 2019 analysis of self-reported health data from over 3,300 cannabis users, researchers reported that THC was more effective than CBD alone in treating chronic pain, insomnia and other medical conditions. Cannabis products containing higher doses of THC provided the most relief.

Another small study conducted in Israel found that “microdosing” small amounts of THC significantly reduced pain levels in patients suffering from neuropathy, without the risks of impairment and other cognitive issues.